Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...
Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...
P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback